



**MCO Amendment 4**  
**Attachment H4 – Changes to Attachment H, Quality Performance Measures**

Item	Change From			Change To			Justification
	Objectives	Measures	Measure Description	Objectives	Measures	Measure Description	
1.	Prevent prematurity and reduce infant mortality	23. Initiation of Injectable Progesterone for Preterm Birth Prevention	The percentage of women 15-45 years of age with evidence of a previous preterm singleton birth event (24-36 weeks completed gestation) who received one or more progesterone injections between the 16th and 24th week of gestation for deliveries during the measurement year.	<del>Prevent prematurity and reduce infant mortality</del>	<del>23. Initiation of Injectable Progesterone for Preterm Birth Prevention</del>	<del>The percentage of women 15-45 years of age with evidence of a previous preterm singleton birth event (24-36 weeks completed gestation) who received one or more progesterone injections between the 16th and 24th week of gestation for deliveries during the measurement year.</del>	<p>The FDA withdrew approval of Makena (progesterone) and its generics for this indication effective April 6, 2023, so this measure is being retired.</p> <p>The objective has been edited to reflect the remaining measure in this category related to reducing infant mortality.</p>
<i>[subsequent measures renumbered]</i>							
2.	38. Colorectal Cancer Screening	\$\$: The percentage of members 50-75 years of age who had appropriate screening for colorectal cancer.		38. Colorectal Cancer Screening	\$\$: The percentage of members <del>50</del> 45-75 years of age who had appropriate screening for colorectal cancer:- <ul style="list-style-type: none"> <li>• <u>46-49 years</u></li> <li>• <u>50-75 years</u></li> <li>• <u>Total</u></li> </ul> <u>The total is the sum of the age stratifications.</u>		NCQA changed the age range beginning in measurement year 2022.